DNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas ...
Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028 MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (ANTX), ...
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results